Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)

• Status: Completed
• Trial end date: 2017-09-15

Summary

This study will assess the safety, tolerability and efficacy of ceftazidime and avibactam (CAZ-AVI )versus cefepime in children from 3 months to less than 18 years old with complicated urinary tract infections.

• Phase: Phase 2

Details

• Lead Sponsor: AstraZeneca; Pfizer
• Collaborator: PRA Health Sciences
• Treatments: Avibactam; Avibactam, ceftazidime drug combination; Cefepime; Ceftazidime; Cephalosporins